Focused On-demand Library for ALK tyrosine kinase receptor

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q9UM73

UPID:
ALK_HUMAN

ALTERNATIVE NAMES:
Anaplastic lymphoma kinase

ALTERNATIVE UPACC:
Q9UM73; A6P4T4; A6P4V4; Q4ZFX9; Q53QQ6; Q53RZ4; Q59FI3; Q9Y4K6

BACKGROUND:
Anaplastic lymphoma kinase (ALK) serves as a critical neuronal receptor tyrosine kinase, essential for nervous system development. It regulates energy expenditure and plays a significant role in the resistance to weight gain. Activation of ALK by specific ligands leads to the phosphorylation of various substrates, driving key signaling pathways involved in cell proliferation, differentiation, and survival.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of ALK tyrosine kinase receptor could open doors to potential therapeutic strategies. Its association with neuroblastoma 3, a disease arising from embryonic cells of the neural crest, positions ALK as a promising target for developing treatments aimed at this and potentially other related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8080 of 8789